V503
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Papillomavirus Infections
Conditions
Papillomavirus Infections
Trial Timeline
Apr 27, 2019 → Feb 28, 2025
NCT ID
NCT03903562About V503
V503 is a phase 3 stage product being developed by Merck for Papillomavirus Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT03903562. Target conditions include Papillomavirus Infections.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04635423 | Phase 3 | Completed |
| NCT03903562 | Phase 3 | Completed |
| NCT03158220 | Phase 3 | Completed |
| NCT01254643 | Phase 3 | Completed |
| NCT00943722 | Phase 3 | Completed |
Competing Products
20 competing products in Papillomavirus Infections